Channel Flushing & Mechanical Action
Automated cleaning cycles reduce residual soil before high-level disinfection.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (Desktop, Floor Standing, Portability, Other), By Application (Hospital, Clinic, Other), By Automation Level (Manual-Assisted Systems, Automated Endoscope Reprocessors, Integrated Cleaning + HLD Systems), By Workflow Configuration (Single-Basin, Dual-Basin, Pass-Through Systems), By Disinfection Chemistry (OPA-Based, Peracetic Acid-Based, Other Validated Chemistries), and Regional Forecast, 2026-2034
The global endoscope cleaning and disinfection system market was valued at USD 1.20 billion in 2025 and is estimated at USD 1.30 billion in 2026. The market is projected to reach USD 2.50 billion by 2034, representing an 8.5% CAGR during 2026–2034.
Endoscope cleaning and disinfection systems are used to reprocess reusable flexible endoscopes between patients. The workflow combines meticulous cleaning with high-level disinfection or liquid chemical sterilization, channel flushing, rinsing and drying. Automated endoscope reprocessors improve consistency, documentation and throughput compared with fully manual handling.
Infection prevention is the central demand driver. CDC states that heat-sensitive gastrointestinal endoscopes, bronchoscopes and similar semicritical devices must be properly cleaned and subjected to at least high-level disinfection after each use. FDA describes automated endoscope reprocessors as Class II devices and requires rigorous validation, particularly for complex devices such as duodenoscopes.
Commercial systems increasingly automate more of the reprocessing cycle. ASP’s AEROFLEX automates washing and high-level disinfection in a 22-minute cycle, while STERIS MEDIVATORS ADVANTAGE PLUS provides validated cleaning and HLD in a dual-basin system with a 35-minute cycle. Premium systems also add automated concentration checks, cycle documentation and no-touch workflow features.
Source: FDA AER evaluation; CDC endoscope disinfection; CDC recommendations; STERIS AER portfolio; ASP high-level disinfection.
The study defines the global endoscope cleaning and disinfection system market market by the equipment, application, end-user and technology boundaries listed below. The scope is structured to keep market sizing consistent with the commercial systems and services included in the syndicated study.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD billion |
| By Type | Desktop; Floor Standing; Portability; Other |
| By Application | Hospital; Clinic; Other |
| By Automation Level | Manual-Assisted Systems; Automated Endoscope Reprocessors; Integrated Cleaning + HLD Systems |
| By Workflow Configuration | Single-Basin; Dual-Basin; Pass-Through Systems |
| By Disinfection Chemistry | OPA-Based; Peracetic Acid-Based; Other Validated Chemistries |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; Germany; France; United Kingdom; Italy; China; Japan; South Korea; India; Australia; Brazil and other relevant markets |
| Key Market Players | STERIS / MEDIVATORS; Advanced Sterilization Products; Olympus; Wassenburg Medical; Getinge; Steelco; Belimed; Miele; Shinva Medical Instrument; B. Braun |
The market includes systems designed to clean, disinfect and reprocess reusable flexible endoscopes, including automated endoscope reprocessors, compact systems and integrated cleaning/high-level-disinfection equipment.
Standalone detergents sold without system linkage, endoscope storage cabinets, sterilizers not intended for endoscope reprocessing and disposable endoscopes are outside the core equipment revenue boundary.
CDC states that heat-sensitive flexible endoscopes must be cleaned and receive at least high-level disinfection after each patient use. This creates non-discretionary equipment demand.
FDA highlights long narrow channels and duodenoscope elevator areas as difficult reprocessing locations. Validation performance is therefore a major competitive requirement.
FDA expects validated reprocessing capable of achieving a 99.9999% microbial reduction in high-level-disinfection validation locations for duodenoscopes.
Endoscopy centers need rapid instrument turnaround. Shorter validated cycles allow a smaller endoscope fleet to support more procedures.
FDA continues to recommend thorough manual cleaning according to endoscope manufacturer instructions even where an AER includes automated steps.
Source: FDA; CDC; ASP AEROFLEX; STERIS.
Premium reprocessors now automate cleaning as well as high-level disinfection, reducing manual steps and documentation burden.
Pass-through systems support unidirectional workflow and reduce the chance that processed endoscopes re-enter contaminated work areas.
ASP systems can automate minimum recommended or effective concentration checks rather than relying only on manual test strips.
Systems with two independently timed basins allow endoscopes to be started and completed at different times, supporting busy departments.
Hospitals increasingly require traceable reprocessing records that link cycle conditions, endoscopes and operators.
Source: STERIS portfolio; ASP HLD; ASP AEROFLEX.
Modern systems combine fluid circulation, channel irrigation, disinfectant exposure, rinsing and increasingly automated verification.
Automated cleaning cycles reduce residual soil before high-level disinfection.
Systems expose endoscope surfaces and channels to approved high-level disinfectants for validated contact time and concentration.
Sensors and software verify process conditions and create a cycle record.
Equipment layout helps separate dirty and clean zones and reduce cross-contamination.
By type, the market is segmented into desktop, floor-standing, portable and other systems. Floor-standing systems lead because high-volume facilities require greater capacity, automation and workflow integration.
Desktop systems target smaller clinics and lower-volume endoscopy units where floor space and capital budget are constrained.
Floor-standing reprocessors support higher-capacity processing, larger basins and more advanced automation.
Portable or mobile systems serve decentralized and specialty environments where fixed installation is less practical.
Other designs include pass-through, multi-basin and procedure-specific configurations.
Floor-standing systems will remain the largest value segment, while compact and portable equipment should expand access in smaller facilities.
By application, the market is segmented into hospitals, clinics and other settings. Hospitals are the leading application because they manage the highest endoscopy volumes and the broadest range of complex reusable scopes.
Hospitals operate gastroenterology, pulmonology, urology and surgical endoscopy services and require validated high-throughput reprocessing.
Specialty clinics need compact and reliable systems for lower procedure volumes and limited reprocessing space.
Other applications include ambulatory surgery centers, diagnostic centers and research or training facilities.
Hospitals will remain the largest application, while clinics and ambulatory facilities support demand for compact and faster systems.
By automation level, the market is segmented into manual-assisted systems, automated endoscope reprocessors, and integrated cleaning plus HLD systems. Automated reprocessors are the leading category.
Manual or semi-automated approaches rely more heavily on staff steps and are most common in low-volume or budget-constrained settings.
AERs automate high-level disinfection and standardized channel exposure and are widely used in hospitals.
Advanced systems automate validated cleaning as well as disinfection, reducing manual steps and improving traceability.
Integrated systems should gain share because labor savings and process consistency justify premium pricing in high-volume departments.
By workflow configuration, the market is segmented into single-basin, dual-basin and pass-through systems. Dual-basin systems lead high-volume use because asynchronous processing improves throughput.
Single-basin systems minimize footprint and acquisition cost for smaller departments.
Dual asynchronous basins allow separate scopes to be processed on different schedules.
Pass-through equipment supports unidirectional dirty-to-clean workflow and helps reduce cross-contamination.
Dual-basin and pass-through systems should capture increasing value as large endoscopy centers focus on throughput and clean-workflow separation.
By disinfection chemistry, the market is segmented into OPA-based, peracetic-acid-based and other validated chemistries. OPA and peracetic acid are widely established in high-level-disinfection workflows.
Ortho-phthalaldehyde is used in flexible-endoscope high-level disinfection and offers relatively short labeled exposure times in suitable systems.
Peracetic-acid systems provide strong antimicrobial activity and are used in liquid chemical processing platforms.
Other options include hydrogen-peroxide combinations and manufacturer-specific chemistries validated for compatible devices.
Chemistry selection will remain driven by endoscope compatibility, contact time, occupational handling and validation with the specific reprocessor.
Regional demand follows endoscopy volumes, infection-control regulation and hospital capital investment. North America is the largest market and Asia-Pacific provides the strongest long-term expansion.
The United States has stringent FDA reprocessing requirements, high endoscopy volumes and a large installed AER base.
Europe combines strict reprocessing standards with strong suppliers such as Wassenburg, Getinge, Steelco and Miele.
China, Japan, South Korea and India are expanding endoscopy infrastructure and hospital infection-control investment.
Demand is concentrated in major hospitals and private diagnostic networks.
Gulf health systems adopt premium equipment while broader growth depends on endoscopy infrastructure.
Endoscope reprocessing systems are regulated around demonstrated cleaning and disinfection effectiveness, device compatibility and validated instructions for use.
| Framework / Event | Requirement or Development | Commercial Relevance |
|---|---|---|
| Class II AER status | FDA identifies AERs as Class II devices cleared through the 510(k) pathway. | Creates formal validation and premarket requirements. |
| Manual cleaning requirement | FDA continues to recommend thorough manual cleaning of duodenoscopes before AER high-level disinfection. | Prevents overreliance on automation. |
| CDC high-level disinfection | CDC requires at least high-level disinfection for heat-sensitive endoscopes after use. | Makes reprocessing a mandatory clinical workflow. |
| Validation data | FDA requires reprocessing validation for selected complex reusable devices and AER-related submissions. | Raises technical barriers to market entry. |
Source: FDA AER; FDA validation appendix; CDC.
Competition is concentrated among established sterile-processing and endoscopy companies with validated device compatibility and hospital service networks.
STERIS offers ADVANTAGE PLUS, pass-through, DSD EDGE and other reprocessing systems spanning different throughput needs.
ASP competes with EVOTECH and AEROFLEX systems that automate endoscope cleaning and/or HLD.
These companies compete through endoscope compatibility, regional installed base, workflow and service.
2026: STERIS continued commercialization of ADVANTAGE PLUS and enspire AER platforms with validated cleaning/HLD claims, dual-basin processing and pass-through workflow options.
2026: ASP continued marketing AEROFLEX with a 22-minute complete cycle and automated concentration monitoring.
Current FDA oversight: FDA continues to publish AER validation status for duodenoscope reprocessing and to evaluate reprocessing effectiveness.
Current infection-control practice: CDC continues to require meticulous cleaning before high-level disinfection of flexible endoscopes.
Source: STERIS; ASP AEROFLEX; FDA; CDC.
The global endoscope cleaning and disinfection system market market is projected to grow from USD 1.30 billion in 2026 to USD 2.50 billion by 2034, at a 8.5% CAGR during 2026–2034. Growth is expected to be supported by rising endoscopy volumes, stricter infection-control practice and hospital replacement of manual or older reprocessing equipment. Premium value should shift toward systems that combine cleaning, HLD, faster cycles, automated monitoring and digital traceability.
| Forecast Variable | Current Evidence / Starting Point | Expected Effect Through 2034 |
|---|---|---|
| Mandatory reprocessing | Every reusable flexible endoscope requires validated cleaning and disinfection. | Creates recurring equipment need. |
| Automation | Integrated systems reduce manual variability. | Supports replacement demand. |
| Throughput | Shorter cycles improve endoscope utilization. | Raises value in busy centers. |
| Traceability | Digital cycle documentation supports quality systems. | Drives premium features. |
| Asia-Pacific expansion | Endoscopy infrastructure is growing quickly. | Provides long-term geographic growth. |
The study is structured to support strategy, market-entry assessment, portfolio planning, competitive benchmarking and commercial opportunity analysis across the global endoscope cleaning and disinfection system market landscape.
24LifeScience develops endoscope cleaning and disinfection system market market estimates using a combination of bottom-up and top-down assessment. Bottom-up work reviews relevant manufacturers, product portfolios, geographic presence, installation or utilization patterns, commercial channels and pricing structure. Top-down work evaluates the addressable testing or diagnostic environment, installed capacity, procedure or production demand, replacement and upgrade cycles, and regional access conditions.
Primary research is used to validate market structure, purchasing criteria, technology adoption, competitive positioning and operating constraints where available. Secondary research prioritizes regulators, government and public-health agencies, recognized standards, peer-reviewed or professional evidence, and company filings or official product communications. The analysis combines current FDA and CDC reprocessing requirements with primary product information from leading AER manufacturers. The displayed 2026 and 2034 values reconcile to an 8.5% CAGR.
Forecasts incorporate the 2025 market base, 2026 estimated conditions, technology and regulatory developments, replacement or expansion demand, regional investment, pricing pressure, service requirements and competitive intensity. High-impact assumptions are cross-checked against authoritative evidence before publication.
The market was valued at USD 1.20 billion in 2025 and is estimated at USD 1.30 billion in 2026. It is projected to reach USD 2.50 billion by 2034 at an 8.5% CAGR during 2026–2034.
Floor-standing systems lead because high-volume hospitals require larger capacity and advanced automation.
Hospitals are the leading application because they process the greatest number and variety of reusable flexible endoscopes.
North America is the largest regional market due to high procedure volumes and stringent reprocessing requirements.
An AER is a Class II device that automates high-level disinfection and, in some systems, validated cleaning of reusable endoscopes.
Yes. FDA continues to emphasize thorough manual cleaning for complex endoscopes according to manufacturer instructions.
Integrated cleaning plus HLD, dual asynchronous basins, pass-through workflow and automated disinfectant-concentration monitoring are gaining importance.
The report profiles STERIS/MEDIVATORS, ASP, Olympus, Wassenburg, Getinge, Steelco, Belimed, Miele, Shinva and B. Braun.
The standardized forecast period is 2026–2034, with 2025 as the base year and 2026 as the estimated year.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.